COLLEGE STATION, Texas, June 9, 2026
Matica Biotechnology announced an agreement with University Health Network (UHN) to provide cGMP manufacturing services for an IL-10 adenoviral gene therapy intended for use in lung transplantation. The investigational therapy is designed for delivery to donor lungs during ex vivo lung perfusion (EVLP) prior to transplantation, with the goal of reducing inflammation and improving transplant outcomes.
Partnership Supports Development of IL-10 Adenoviral Gene Therapy
Under the agreement, Matica Bio will provide comprehensive development and manufacturing services, including research cell bank generation, adenovirus seed synthesis and amplification, process development, analytical testing, virus bank production, and cGMP manufacturing of the adenoviral vector. The collaboration is intended to support the advancement of the therapy toward future clinical development and potential evaluation in lung transplant patients.
EVLP and Gene Therapy Combination Aims to Improve Transplant Success
The investigational therapy utilizes interleukin-10 (IL-10), an anti-inflammatory cytokine, delivered through an adenoviral vector during ex vivo lung perfusion, a technology that allows donor lungs to be assessed and treated outside the body before transplantation. Researchers believe combining EVLP with gene therapy may help reduce inflammation, improve graft function, and potentially increase the number of donor lungs suitable for transplantation, addressing a significant unmet need in transplant medicine.
Advertisement
Matica Bio Expands Presence in Advanced Therapy Manufacturing
The agreement further strengthens Matica Biotechnology’s position as a viral vector contract development and manufacturing organization (CDMO) supporting advanced therapy programs across gene therapy, immuno-oncology, and regenerative medicine. The company will leverage its expertise in adenoviral vector process development and cGMP production to support the program from early development through clinical manufacturing.
Source: Matica Biotechnology press release
